1.059

93-01-02

PTO/SB/05 (03-01)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it displays a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to

UTILITY PATENT APPLICATION **TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR

e required	to respond to a conecti	off of intoffication discools adoptayo a valid office domination				
Attorney Docket No.		LEX-0314-USA				
First Inventor		Wilganowski				
Title	Novel Human Transporter Proteins and Polynucleotides Encoding the Same					

	1.53 (b))	Express Mail Label No. EV 088047915 US						
	APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application	ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, DC 20231						
	Fee Transmittal Form (e.g., PTO/SB/17) Applicant claims small entity status. See 37 CFR 1.27.	7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)						
	3. X Specification [Total Pages (preferred arrangement set forth below) 36	a. X Computer Readable Form (CRF) - DISKETTE						
4l 1l	 Descriptive title of the Invention Cross Reference to Related Applications Statement Regarding Fed sponsored R & D Reference to sequence listing, a table, or a computer program listing appendix Background of the Invention 	 b. Specification Sequence Listing on: i. CD-ROM or CD-R (2 copies); or ii. X paper (5 pages) c. X Statements verifying identity of above copies 						
# #	- Brief Buschard And Wrawings (if filed)	ACCOMPANYING APPLICATION PARTS						
T T	- Detailed Description - Claim(s) - Abstract of the disclosure	9. Assignment Papers (cover sheet & document(s))						
Į,	Drawing(s) (35 U.S.C.113) [Total	10. 37 CFR 3.73(b) Statement (when there is an assignee) X Power of Attorney						
1	4. Sheets	11. English Translation Document (if applicable) 12. Information Disclosure Copies of IDS Copies of IDS Citations						
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	5. Oath or Declaration [Total Pages 2] 1 a. X Unexecuted (original or copy)	13. Statement (IDS)/PTO-1449 Citations 13. Preliminary Amendment						
	b. Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 18 completed)	14. X Return Receipt Postcard (MPEP 503) (Should be specifically itemized)						
	i. DELETION OF INVENTOR(S) signed statement attached deleting inventor(s)	15. Certified Copy of Priority Document(s) (if foreign priority is claimed)						
	named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).	16. Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent						
	6. Application Data Sheet. See 37 CFR 1.76	17. Other:						
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:								
	Continuation Divisional Continuation							
Prior application information: Examiner Group Art Unit: For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.								
	19. CORRE	SPONDENCE ADDRESS						
	X Customer Number or Bar Code Label	or Attach bar code label here) or Correspondence address below						
	Name 242	231						
	PATENT TRADE	EMARK OFFICE						
	Address							
	City State	Zip						
	Country Telephon	Fax						
	Name (Print/Type) Lance K. Ishimoto	Registration No. (Attorney/Agent) 41,866						
	Lance K. Solumoa by De	and W. Hotel						

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant

PTO/SB/17 (11-01)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

		- 					
	TTAI	Complete if Known					
FEE TRANSMI	IIAL	Application Number	Not Yet Assigned				
for EV 200	a	Filing Date	March 6, 2002				
for FY 200	_	First Named Inventor	Wilganowski et al.				
Patent fees are subject to annual re	vision.	Examiner Name	Not Yet Assigned				
Applicant claims small entity status. See 37 CFR 1.27		Group Art Unit	Not Yet Assigned				
TOTAL AMOUNT OF PAYMENT	(\$) 740.00	Attorney Docket No.	LEX-0314-USA				

METHOD OF DAVIS	1	EEE CALCIII ATION (continued)					
METHOD OF PAYMENT (check all that apply)			FEE CALCULATION (continued)				
Check Credit Card Money Other None			3. ADDITIONAL FEES Large Entity Small Entity				
			Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
X Deposit Account			130	205	65	Surcharge - late fling fee or oath	
Deposit						Surcharge - late provisional filing fee or cover	
Account Number 50-0892		127	50	227	25	sheet	
Deposit Account		139	130	139	130	Non-English specification	
Name		100	150	'00	100	Tron English spoomed.or	<u> </u>
The Commissioner is authorize	zed to: (check all that apply)	147	2,520	147	2,520	For filing a request for ex parte	
Charge fee(s) indicated	d below Credit any overpayments	112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
Charge any additional fee(s) during the pendency of this application			1,840*	113	1,840**	Requesting publication of SIR after Examiner action	
Charge fee(s) indicated below, except for the filing fee			110	215	55	Extension for reply within first month	
to the above-identified deposit	account.	116	400	216	200	Extension for reply within second month	
FEE (CALCULATION	117	920	217	460	Extension for reply within third month	
1. BASIC FILING FEE	<u> </u>	118	1,440	218	720	Extension for reply within fourth month	
Large Entity Small Ent	ity	128	1,960	228	980	Extension for reply within fifth month	
	ee <u>Fee Description</u> \$) Fee Paid	119	320	219	160	Notice of Appeal	
,,,	70 Utility filing fee 740.00	120	320	220	160	Filing a brief in support of an appeal	
106 330 206 1	65 Design filing fee	121	280	221	140	Request for oral hearing	
107 510 207 .2	55 Plant filing fee	138	1,510	138	1,510	Petition to institute a public use proceeding	
108 740 208 3	70 Reissue filing fee	140	110	240	55	Petition to revive - unavoidable	
114 160 214 8	30 Provisional filing fee	141	1,280	241	640	Petition to revive - unintentional	
•	SUBTOTAL (1) (\$) 740.00	142	1,280	242	640	Utility issue fee (or reissue)	\vdash
EXTRA CLAIM FEE	S FOR UTILITY AND REISSUE	143	460	243	230	Design issue fee	
	Fee from	144	620	244	310	Plant issue fee	
fotal Claims -20**=	tra Claims below Fee Paid	122	130	122	130	Petitions to the Commissioner	
			ro	100	50	December 400 under 27 CER 1 17/g)	
· L	× =	123	50	123	50	Processing fee under 37 CFR 1.17(q)	
Multiple Dependent	=	126	180	126	180	Submission of Information Disclosure Stmt	
Large Entity Small En	tity	581	40	581	40	Recording each patent assignment per property (times number of properties)	1
	ee \$) <u>Fee Description</u>	146	740	246	370	Filing a submission after final rejection (37 CFR § 1.129(a))	
	9 Claims in excess of 20 12 Independent claims in excess of 3	149	740	249	370	For each additional invention to be	
	40 Multiple dependent claim, if not paid			- "	-	examined (37 CFR § 1.129(b))	
109 84 209 4	**Reissue independent claims over original patent	179	740	279	370	Request for Continued Examination (RCE)	
110 18 210	9 ** Reissue claims in excess of 20 and over original patent	169	900	169	900	Request for expedited examination of a design application	
	SUBTOTAL (2) (\$)	Other	fee (speci	ly)			
**or number previously na	aid if greater For Reissues, see above	*Redu	ced by Ba	sic Filino	ı Fee Pai	id SUBTOTAL (3)	
**or number previously paid, if greater; For Reissues, see above			,				

SUBMITTED BY Complete (if applicable)						
Name (Print/Type)	Lance K. Ishimoto	Registration No. (Attorney/Agent)	41,866	Telephone	(281) 863-3333	
Signature	Lance K. Whenvite by Dovid V		10 W. HBLER No. 41,071	Date	March 6, 2002	

WARNING: Information on this form may become public. Cr dit card inf rmation should not be included on this form. Provide credit card information and authorization of PTO-2038.

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant:

Wilganowski et al.

U.S. Ser. No.:

To be assigned

Attorney Docket No.: LEX-0314-USA

Filing Date:

March 6, 2002

For:

Novel Human Transporter Proteins and Polynucleotides Encoding the

Same

VERIFIED STATEMENT

Box Patent Application Commission for Patents Washington, D.C. 20231

Sir:

- I, DRENDA D. THOMAS, do declare and state as follows:
- 1. I prepared a Sequence Listing in paper and computer readable form under 37 C.F.R. Sec. 1.821-1.825 in connection with the above-captioned patent application, both of which are being submitted herewith.
- 2. I hereby state that the contents of the paper and computer readable copies of the Sequence Listing are the same.

Signed,

March 6, 2002

Date

Drenda D. Thomas